GC Biopharma Corp. (KRX:006280)
131,300
+600 (0.46%)
At close: Nov 4, 2025
GC Biopharma Revenue
GC Biopharma had revenue of 500.26B KRW in the quarter ending June 30, 2025, with 19.86% growth. This brings the company's revenue in the last twelve months to 1.79T, up 10.58% year-over-year. In the year 2024, GC Biopharma had annual revenue of 1.68T with 3.27% growth.
Revenue (ttm)
1.79T
Revenue Growth
+10.58%
P/S Ratio
0.84
Revenue / Employee
876.47M
Employees
2,042
Market Cap
1.50T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.68T | 53.25B | 3.27% |
| Dec 31, 2023 | 1.63T | -84.67B | -4.95% |
| Dec 31, 2022 | 1.71T | 173.49B | 11.28% |
| Dec 31, 2021 | 1.54T | 33.71B | 2.24% |
| Dec 31, 2020 | 1.50T | 147.00B | 10.83% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| SK Biopharmaceuticals | 620.28B |
| PharmaResearch | 449.81B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |